{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:57:25Z","timestamp":1788371845494,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10096-025-05335-x","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:02:03Z","timestamp":1761825723000},"page":"459-467","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative in vitro analysis of sulbactam-durlobactam against extensively drug resistant (XDR) and non-XDR carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates collected from a tertiary care facility in North India"],"prefix":"10.1007","volume":"45","author":[{"given":"Neha","family":"Nityadarshini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitender","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamanna","family":"Bordoloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyam","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benu","family":"Dhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimal Kumar","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"5335_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1128\/CMR.00058-16","volume":"30","author":"D Wong","year":"2017","unstructured":"Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B (2017) Clinical and pathophysiological overview of acinetobacter infections: a century of challenges. Clin Microbiol Rev 30:409\u2013447. https:\/\/doi.org\/10.1128\/CMR.00058-16","journal-title":"Clin Microbiol Rev"},{"key":"5335_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9030119","volume":"9","author":"C Ayoub Moubareck","year":"2020","unstructured":"Ayoub Moubareck C, Hammoudi Halat D (2020) Insights into acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics 9:119. https:\/\/doi.org\/10.3390\/antibiotics9030119","journal-title":"Antibiotics"},{"key":"5335_CR3","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"M Naghavi","year":"2024","unstructured":"Naghavi M, Vollset SE, Ikuta KS et al (2024) Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050. Lancet 404:1199\u20131226. https:\/\/doi.org\/10.1016\/S0140-6736(24)01867-1","journal-title":"Lancet"},{"key":"5335_CR4","volume-title":"WHO bacterial priority pathogens list 2024: bacterial pathogens of public health importance, to guide research, development and strategies to prevent and control antimicrobial resistance","author":"World Health Organization","year":"2024","unstructured":"World Health Organization (2024) WHO bacterial priority pathogens list 2024: bacterial pathogens of public health importance, to guide research, development and strategies to prevent and control antimicrobial resistance. WHO, Geneva. https:\/\/www.who.int\/publications\/i\/item\/9789240093461"},{"key":"5335_CR5","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s40121-022-00597-w","volume":"11","author":"C Bartal","year":"2022","unstructured":"Bartal C, Rolston KVI, Nesher L (2022) Carbapenem-resistant acinetobacter baumannii: colonization, infection and current treatment options. Infect Dis Ther 11:683\u2013694. https:\/\/doi.org\/10.1007\/s40121-022-00597-w","journal-title":"Infect Dis Ther"},{"key":"5335_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab026","volume":"8","author":"K Eljaaly","year":"2021","unstructured":"Eljaaly K, Bidell MR, Gandhi RG et al (2021) Colistin nephrotoxicity: meta-analysis of randomized controlled trials. Open Forum Infect Dis 8:ofab026. https:\/\/doi.org\/10.1093\/ofid\/ofab026","journal-title":"Open Forum Infect Dis"},{"key":"5335_CR7","doi-asserted-by":"publisher","unstructured":"Tamma PD (2024) Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis 78. https:\/\/doi.org\/10.1093\/cid\/ciae403. :in press","DOI":"10.1093\/cid\/ciae403"},{"key":"5335_CR8","unstructured":"Food US, Administration D (2023) FDA approves new treatment for pneumonia caused by certain difficult-to-treat bacteria. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-pneumonia-caused-certain-difficult-treat-bacteria (Press release, 23 May 2023)"},{"issue":"Suppl 2","key":"5335_CR9","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.1093\/cid\/ciad093","volume":"76","author":"RR Watkins","year":"2023","unstructured":"Watkins RR, Bonomo RA (2023) Sulbactam-durlobactam: a step forward in treating carbapenem-resistant acinetobacter baumannii infections. Clin Infect Dis 76(Suppl 2):S163\u2013S165. https:\/\/doi.org\/10.1093\/cid\/ciad093","journal-title":"Clin Infect Dis"},{"key":"5335_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/jac\/47.4.479","volume":"47","author":"MJ Rodr\u00edguez-Hern\u00e1ndez","year":"2001","unstructured":"Rodr\u00edguez-Hern\u00e1ndez MJ, Cuberos L, Pichardo C et al (2001) Sulbactam efficacy in experimental models caused by susceptible and intermediate acinetobacter baumannii strains. J Antimicrob Chemother 47:479\u2013482. https:\/\/doi.org\/10.1093\/jac\/47.4.479","journal-title":"J Antimicrob Chemother"},{"key":"5335_CR11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","volume":"24","author":"J Liu","year":"2021","unstructured":"Liu J, Shu Y, Zhu F et al (2021) Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for MDR\/XDR acinetobacter baumannii infections: a systematic review and network meta-analysis. J Glob Antimicrob Resist 24:136\u2013147. https:\/\/doi.org\/10.1016\/j.jgar.2020.08.021","journal-title":"J Glob Antimicrob Resist"},{"key":"5335_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2217\/fmb-2023-0248","volume":"19","author":"SM McLeod","year":"2024","unstructured":"McLeod SM, O\u2019Donnell JP, Narayanan N et al (2024) Sulbactam\u2013durlobactam: a \u03b2-lactam\/\u03b2-lactamase inhibitor combination targeting acinetobacter baumannii. Future Microbiol 19:563\u2013576. https:\/\/doi.org\/10.2217\/fmb-2023-0248","journal-title":"Future Microbiol"},{"issue":"Suppl 2","key":"5335_CR13","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1093\/cid\/ciad095","volume":"76","author":"KM Papp-Wallace","year":"2023","unstructured":"Papp-Wallace KM, McLeod SM, Miller AA (2023) Durlobactam, a broad-spectrum serine \u03b2-lactamase inhibitor, restores sulbactam activity against acinetobacter species. Clin Infect Dis 76(Suppl 2):S194\u2013S201. https:\/\/doi.org\/10.1093\/cid\/ciad095","journal-title":"Clin Infect Dis"},{"key":"5335_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.clinthera.2023.11.009","volume":"46","author":"P Beninger","year":"2024","unstructured":"Beninger P (2024) Sulbactam\/durlobactam. Clin Ther 46:82\u201383. https:\/\/doi.org\/10.1016\/j.clinthera.2023.11.009","journal-title":"Clin Ther"},{"key":"5335_CR15","doi-asserted-by":"publisher","first-page":"e00781","DOI":"10.1128\/aac.00781-22","volume":"66","author":"JA Karlowsky","year":"2022","unstructured":"Karlowsky JA, Hackel MA, McLeod SM, Miller AA (2022) In vitro activity of sulbactam-durlobactam against global isolates of acinetobacter baumannii-calcoaceticus complex collected 2016\u20132021. Antimicrob Agents Chemother 66:e00781\u2013e00722. https:\/\/doi.org\/10.1128\/aac.00781-22","journal-title":"Antimicrob Agents Chemother"},{"key":"5335_CR16","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00278-2","volume":"23","author":"KS Kaye","year":"2023","unstructured":"Kaye KS, Shorr AF, Wunderink RG et al (2023) Efficacy and safety of sulbactam\u2013durlobactam versus colistin for serious infections caused by acinetobacter baumannii\u2013calcoaceticus complex: multicentre, randomised, active-controlled, phase 3 non-inferiority trial (ATTACK). Lancet Infect Dis 23:1072\u20131084. https:\/\/doi.org\/10.1016\/S1473-3099(23)00278-2","journal-title":"Lancet Infect Dis"},{"key":"5335_CR17","first-page":"6","volume":"5","author":"M Acharya","year":"2024","unstructured":"Acharya M, Mamoria VP, Kumawat S et al (2024) Prevalence and antimicrobial susceptibility pattern of acinetobacter baumannii complex in clinical samples at a tertiary care hospital, Jaipur. Ann Acad Romanian Sci Ser Med 5:6\u201313","journal-title":"Ann Acad Romanian Sci Ser Med"},{"key":"5335_CR18","doi-asserted-by":"publisher","first-page":"9129083","DOI":"10.1155\/2018\/9129083","volume":"2018","author":"T Banerjee","year":"2018","unstructured":"Banerjee T, Mishra A, Das A et al (2018) High prevalence and endemicity of multidrug-resistant acinetobacter spp. In an ICU of a tertiary care hospital, Varanasi, India. J Pathog 2018:9129083. https:\/\/doi.org\/10.1155\/2018\/9129083","journal-title":"J Pathog"},{"key":"5335_CR19","doi-asserted-by":"publisher","first-page":"e70066","DOI":"10.1002\/hsr2.70066","volume":"7","author":"A Anand","year":"2024","unstructured":"Anand A, Verma A, Kaur S et al (2024) An overview of sulbactam-durlobactam approval and implications in advancing therapeutics for HAP\/VAP by acinetobacter baumannii-calcoaceticus complex: a narrative review. Health Sci Rep 7:e70066. https:\/\/doi.org\/10.1002\/hsr2.70066","journal-title":"Health Sci Rep"},{"key":"5335_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB et al (2012) Multidrug-, extensively drug-, and pan-drug-resistant bacteria: interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268\u2013281. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x","journal-title":"Clin Microbiol Infect"},{"key":"5335_CR21","volume-title":"Performance standards for antimicrobial susceptibility testing. CLSI supplement M100","author":"Clinical and Laboratory Standards Institute","year":"2025","unstructured":"Clinical and Laboratory Standards Institute (2025) Performance standards for antimicrobial susceptibility testing. CLSI supplement M100, 35th edn. CLSI, Wayne, PA","edition":"35"},{"key":"5335_CR22","volume-title":"Performance standards for antimicrobial disk susceptibility testing. CLSI standard M07-A10","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute (2015) Performance standards for antimicrobial disk susceptibility testing. CLSI standard M07-A10. CLSI, Wayne, PA"},{"key":"5335_CR23","doi-asserted-by":"publisher","first-page":"e01228","DOI":"10.1128\/jcm.01228-23","volume":"62","author":"SM McLeod","year":"2024","unstructured":"McLeod SM, Carter NM, Huband MD et al (2024) Sulbactam-durlobactam susceptibility test method development and quality-control ranges for MIC and disk diffusion tests. J Clin Microbiol 62:e01228\u2013e01223. https:\/\/doi.org\/10.1128\/jcm.01228-23","journal-title":"J Clin Microbiol"},{"key":"5335_CR24","volume-title":"Performance standards for antimicrobial disk susceptibility testing. CLSI standard M02-A12","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute (2015) Performance standards for antimicrobial disk susceptibility testing. CLSI standard M02-A12. CLSI, Wayne, PA"},{"key":"5335_CR25","doi-asserted-by":"publisher","first-page":"e02534","DOI":"10.1128\/AAC.02534-19","volume":"64","author":"SM McLeod","year":"2020","unstructured":"McLeod SM, Moussa SH, Hackel MA, Miller AA (2020) In vitro activity of sulbactam-durlobactam against acinetobacter baumannii-calcoaceticus complex isolates collected globally in 2016\u20132017. Antimicrob Agents Chemother 64:e02534\u2013e02519. https:\/\/doi.org\/10.1128\/AAC.02534-19","journal-title":"Antimicrob Agents Chemother"},{"key":"5335_CR26","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1093\/jac\/dkaa119","volume":"75","author":"Q Yang","year":"2020","unstructured":"Yang Q, Xu Y, Jia P et al (2020) In vitro activity of sulbactam\/durlobactam against clinical isolates of Acinetobacter baumannii collected in China. J Antimicrob Chemother 75:1833\u20131839. https:\/\/doi.org\/10.1093\/jac\/dkaa119","journal-title":"J Antimicrob Chemother"},{"key":"5335_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.814530","volume":"11","author":"D Petropoulou","year":"2022","unstructured":"Petropoulou D, Siopi M, Vourli S, Pournaras S (2022) Activity of sulbactam-durlobactam and comparators against a National collection of carbapenem-resistant Acinetobacter baumannii isolates from Greece. Front Cell Infect Microbiol 11:814530. https:\/\/doi.org\/10.3389\/fcimb.2021.814530","journal-title":"Front Cell Infect Microbiol"},{"key":"5335_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11081136","volume":"11","author":"B Segatore","year":"2022","unstructured":"Segatore B, Piccirilli A, Cherubini S et al (2022) In vitro activity of sulbactam\u2013durlobactam against carbapenem-resistant Acinetobacter baumannii clinical isolates: a multicentre report from Italy. Antibiotics 11:1136. https:\/\/doi.org\/10.3390\/antibiotics11081136","journal-title":"Antibiotics"},{"key":"5335_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jgar.2022.07.003","volume":"30","author":"J Findlay","year":"2022","unstructured":"Findlay J, Poirel L, Bouvier M, Nordmann P (2022) In vitro activity of sulbactam-durlobactam against carbapenem-resistant acinetobacter baumannii and mechanisms of resistance. J Glob Antimicrob Resist 30:445\u2013450. https:\/\/doi.org\/10.1016\/j.jgar.2022.07.003","journal-title":"J Glob Antimicrob Resist"},{"key":"5335_CR30","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1089\/mdr.2017.0078","volume":"24","author":"M Rahman","year":"2018","unstructured":"Rahman M, Prasad KN, Gupta S et al (2018) Prevalence and molecular characterization of new Delhi metallo-\u03b2-lactamases in multidrug-resistant Pseudomonas aeruginosa and acinetobacter baumannii from India. Microb Drug Resist 24:792\u2013798. https:\/\/doi.org\/10.1089\/mdr.2017.0078","journal-title":"Microb Drug Resist"},{"key":"5335_CR31","doi-asserted-by":"publisher","first-page":"e01627","DOI":"10.1128\/aac.01627-24","volume":"69","author":"B Veeraraghavan","year":"2025","unstructured":"Veeraraghavan B, Shin E, Bakthavatchalam YD et al (2025) A Microbiological and structural analysis of the interplay between sulbactam\/durlobactam and Imipenem against penicillin-binding proteins of acinetobacter spp. Antimicrob Agents Chemother 69:e01627\u2013e01624. https:\/\/doi.org\/10.1128\/aac.01627-24","journal-title":"Antimicrob Agents Chemother"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05335-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05335-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05335-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:44:44Z","timestamp":1773409484000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05335-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["5335"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05335-x","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Ethics Committee (AIIMSA2632\/06.12.2024).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}